{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:36:41Z","timestamp":1754159801448,"version":"3.41.2"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008017","name":"Gustave Roussy Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008017","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ecl.2025.03.011","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:02:00Z","timestamp":1745852520000},"page":"407-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dosimetry in Advanced Thyroid Cancer"],"prefix":"10.1016","volume":"54","author":[{"given":"Carmela","family":"Nappi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Cras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desiree","family":"Deandreis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ecl.2025.03.011_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamaoto.2021.4549","article-title":"A comparison of the burden of thyroid cancer among the European union 15+ countries, 1990-2019: estimates from the global burden of disease study","volume":"148","author":"Schuster-Bruce","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.011_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1530\/EJE-11-0283","article-title":"BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas","volume":"165","author":"Durante","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.011_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.011_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000354537","article-title":"2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer","volume":"2","author":"Leenhardt","year":"2013","journal-title":"Eur Thyroid J"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.011_bib5","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ecl.2025.03.011_bib6","first-page":"171","article-title":"The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer","volume":"87","author":"Benua","year":"1962","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"issue":"16","key":"10.1016\/j.ecl.2025.03.011_bib7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJM198310203091601","article-title":"Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer","volume":"309","author":"Maxon","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2025.03.011_bib8","first-page":"1317","article-title":"A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131","volume":"2","author":"Benua","year":"1986","journal-title":"Frontiers in Thyroidology"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.011_bib9","first-page":"1132","article-title":"Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetry approach: outcome and validation in 85 patients","volume":"33","author":"Maxon","year":"1992","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.011_bib10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","article-title":"EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy","volume":"35","author":"Lassmann","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.011_bib11","first-page":"1303","article-title":"Initial testing of an approximated, fast calculation procedure for personalized dosimetry in radionuclide therapy based on planar whole-body scan and monte-carlo specific dose rates from the OpenDose project","volume":"12","author":"Bianco","year":"2022","journal-title":"Life (Basel)"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.011_bib12","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","article-title":"EANM practice guideline for quantitative SPECT-CT","volume":"50","author":"Dickson","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.011_bib13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1677\/ERC-09-0076","article-title":"Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma","volume":"16","author":"H\u00e4nscheid","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.011_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s00259-016-3334-4","article-title":"Evaluation of (124) I PET\/CT and (124)I PET\/MRI in the management of patients with differentiated thyroid cancer","volume":"43","author":"Dercle","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.011_bib15","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s00259-010-1565-3","article-title":"Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET\/CT dosimetric comparisons","volume":"37","author":"Freudenberg","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.011_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1095-0397(99)00004-7","article-title":"Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging","volume":"2","author":"Erdi","year":"1999","journal-title":"Clin Positron Imaging"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.011_bib17","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00259-002-0775-8","article-title":"Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET","volume":"29","author":"Eschmann","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.011_bib18","first-page":"1366","article-title":"Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software","volume":"45","author":"Sgouros","year":"2004","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.011_bib19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2967\/jnumed.107.047159","article-title":"Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer","volume":"49","author":"Jentzen","year":"2008","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.011_bib20","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1007\/s00259-023-06240-1","article-title":"The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients","volume":"50","author":"Mauguen","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.011_bib21","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1210\/jc.2011-0494","article-title":"Efficacy of dosimetry versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer","volume":"96","author":"Klubo-Gwiezdzinska","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.011_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2967\/jnumed.116.179606","article-title":"Comparison of empiric versus whole-body\/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer","volume":"58","author":"Deandreis","year":"2017","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.011_bib23","first-page":"451","article-title":"Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach","volume":"44","author":"Dorn","year":"2003","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.011_bib24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00259-009-1261-3","article-title":"A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer","volume":"37","author":"Flux","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.011_bib25","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2967\/jnumed.114.144089","article-title":"Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging","volume":"55","author":"Jentzen","year":"2014","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.011_bib26","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2967\/jnumed.115.168799","article-title":"Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET\/CT","volume":"57","author":"Wierts","year":"2016","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.011_bib27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2967\/jnumed.115.170571","article-title":"124I PET assessment of response of bone metastases to initial radioiodine treatment of differentiated thyroid cancer","volume":"57","author":"Jentzen","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ecl.2025.03.011_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-024-11249-7","article-title":"A visual scale to rate amygdalar atrophy on MRI","author":"Pizzini","year":"2024","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.011_bib29","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.011_bib30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2967\/jnumed.122.264913","article-title":"The role of pretherapy quantitative imaging and dosimetry in radioiodine therapy for advanced thyroid cancer","volume":"64","author":"Taprogge","year":"2023","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.011_bib31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1089\/thy.2006.16.1019","article-title":"The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer","volume":"16","author":"Kulkarni","year":"2006","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.011_bib32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12149-012-0632-1","volume":"26","author":"Hartung-Knemeyer","year":"2012","journal-title":"Ann Nucl Med"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.011_bib33","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/sj.bjc.6601319","article-title":"Second primary malignancies in thyroid cancer patients","volume":"89","author":"Rubino","year":"2003","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.011_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/cen.12581","article-title":"The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131) I dose over 37 GBq","volume":"83","author":"Khang","year":"2015","journal-title":"Clin Endocrinol (Of)"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.011_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40658-020-00332-9","article-title":"Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project","volume":"7","author":"Taprogge","year":"2020","journal-title":"EJNMMI Phil"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.011_bib36","article-title":"Absorbed dose coefficients for adult thyroid cancer patients undergoing radioiodine therapy","volume":"43","author":"Kwon","year":"2023","journal-title":"J Radilo Proti"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.011_bib37","first-page":"1549","article-title":"Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer","volume":"45","author":"de Keizer","year":"2004","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.011_bib38","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s00259-010-1565-3","article-title":"L\u00e4sion dose in differentiale Thyrsoi carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET\/CT dosimetric comparisons","volume":"37","author":"Freudenberg","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.011_bib39","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.2967\/jnumed.116.179366","article-title":"Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I PET\/CT-Based dosimetry for 131I therapy of metastatic differentiated thyroid cancer","volume":"58","author":"Plyku","year":"2017","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.011_bib40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.14310\/horm.2002.11193","article-title":"Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetry, radiation safety, and practical considerations","volume":"5","author":"Alevizaki","year":"2006","journal-title":"Hormones (Athens)"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.011_bib41","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2967\/jnumed.119.232017","article-title":"Management of patients with renal failure undergoing dialysis during 131I therapy for thyroid cancer","volume":"61","author":"Vermandel","year":"2020","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.011_bib42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s12022-019-09593-2","article-title":"Molecular heterogeneity of papillary thyroid cancer: comparison of primary tumors and synchronous metastases in regional lymph nodes by mass spectrometry imaging","volume":"30","author":"Gawin","year":"2019","journal-title":"Endocr Pathol"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.011_bib43","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","volume":"92","author":"Durante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4260","key":"10.1016\/j.ecl.2025.03.011_bib44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumour cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"issue":"7381","key":"10.1016\/j.ecl.2025.03.011_bib45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.011_bib46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: a looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.011_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017933","article-title":"Solving the puzzle of metastasis: the evolution of cell migration in neoplasms","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.011_bib48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ecl.2025.03.011_bib49","article-title":"EANM expert opinion: how can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses","author":"Puget","year":"2024","journal-title":"Eur J Null Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.011_bib50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semradonc.2020.07.002","article-title":"The radiobiology of radiopharmaceuticals","volume":"31","author":"Morris","year":"2021","journal-title":"Semen Radiate Uncool"},{"issue":"6B","key":"10.1016\/j.ecl.2025.03.011_bib51","first-page":"781","article-title":"Whole-body irradiation and long-term modification of bone marrow-derived cell populations by low- and high-LET radiation","volume":"20","author":"Gridley","year":"2006","journal-title":"In Vivo (Athens)"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.011_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0167-8140(85)80122-5","article-title":"Effect of dose-rate on total body irradiation: lethality and pathologic findings","volume":"4","author":"Travis","year":"1985","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.011_bib53","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1073\/pnas.090099497","article-title":"Inverse radiation dose-rate effects on somatic and germ-line mutations and DNA damage rates","volume":"97","author":"Vilenchik","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.011_bib54","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2967\/jnumed.105.028183","article-title":"MIRD continuing education: bystander and low dose-rate effects: are these relevant to radionuclide therapy?","volume":"48","author":"Sgouros","year":"2007","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.011_bib55","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.3390\/ijms25105493","article-title":"Modelling the in vivo and ex vivo DNA damage response after internal irradiation of blood from patients with thyroid cancer","volume":"25","author":"Schumann","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.011_bib56","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12350-019-01747-3","article-title":"Diagnostic performance of myocardial perfusion imaging with conventional and CZT single-photon emission computed tomography in detecting coronary artery disease: a meta-analysis","volume":"28","author":"Cantoni","year":"2021","journal-title":"J Nucl Cardiol"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.011_bib57","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1007\/s00259-024-06718-6","article-title":"Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [177Lu] Lu-PSMA-617 in metastatic castration-resistant prostate cancer","volume":"51","author":"Song","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:03:03Z","timestamp":1753484583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0889852925000337"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.011","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetry in Advanced Thyroid Cancer","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}